Actually, pembrolizumab seems to be more effective in CCA patients with microsatellite instability (MSI) or mismatch repair deficiency (dMMR) whose incidence is low in CCA while it is also reported that the number of ECC patients with PDL1 positive could be small (161, 162). The gene discussed is CD274; the disease is cholangiocarcinoma.